安罗替尼与阿帕替尼分别联合替吉奥治疗晚期食管癌的效果比较  

Comparison of Efficacy of Anlotinib and Apatinib Combined with Tegafur in the Treatment of Advanced Esophageal Cancer

作　　者：闫睿[1] 闫桂芳[2] YAN Rui;YAN Gui-fang(Department of Oncology,Jiyuan Tumor Hospital,Jiyuan 459000,Henan Province,China;Department of Internal Medicine,Jiyuan Second People's Hospital,Jiyuan 459000,Henan Province,China)

机构地区：[1]济源市肿瘤医院肿瘤内科,河南济源459000 [2]济源市第二人民医院内二科,河南济源459000

出　　处：《罕少疾病杂志》2024年第9期47-49,共3页Journal of Rare and Uncommon Diseases

摘　　要：目的 探讨安罗替尼与阿帕替尼分别联合替吉奥治疗晚期食管癌的临床效果。方法 选取2020年10月~2021年10月本院收治的126例晚期食管癌患者作为研究对象,按随机数字表法分为两组。对照组63例给予阿帕替尼联合替吉奥治疗,观察组63例给予安罗替尼联合替吉奥治疗。对比两组客观缓解率(ORR)、疾病控制率(DCR)、中位总生存期(OS)、无进展生存期(PFS)、治疗期间不良反应发生情况;另比较两组治疗前后Karnofsky功能状态(KPS)评分和食管癌专用量表(QLQ-OES24)评分。结果 观察组ORR、DCR均高于对照组(30.16%比14.29%、76.19%比58.73%,P<0.05);观察组患者的OS、PFS均长于对照组[(7.23±1.32)个月比(6.43±1.22)个月、(3.67±0.69)个月比(3.23±0.58)个月,P<0.05];两组不良反应发生率差异无统计学意义(P>0.05);治疗后两组KPS、QLQ-OES24评分均升高(P<0.05),且观察组均高于对照组(P<0.05)。结论 安罗替尼与阿帕替尼联合替吉奥治疗晚期食管癌均有一定的治疗效果,但相较于阿帕替尼联合替吉奥,安罗替尼联合替吉奥治疗更有利于延长患者无进展生存时间和中位总生存期,提高近期疗效,改善患者生活质量,且安全性良好。Objective To investigate the clinical effect of anlotinib and alpatinib combined with tegafur in the treatment of advanced esophageal cancer.Methods 126 patients with advanced esophageal cancer admitted to our hospital from October 2020 to October 2021 were selected as research objects,and they were divided into two groups according to random number table.63 cases in the control group were treated with alpatinib combined with tegafur,while 63 cases in the observation group were treated with anlotinib combined with tegafur.Response rate(ORR),disease control rate(DCR),median total survival(OS),progression free survival(PFS)and adverse reactions during treatment were compared between the two groups.In addition,Karnofsky functional status(KPS)scores and esophageal cancer specific scale(QLQ-OES24)scores were compared between the two groups before and after treatment.Results The ORR and DCR in the observation group were higher than those in the control group(30.16%vs.14.29%,76.19%vs.58.73%,P<0.05).OS and PFS of patients in the observation group were longer than those in the control group[(7.23±1.32)months vs.(6.43±1.22)months,(3.67±0.69)months vs.(3.23±0.58)months,P<0.05].There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,KPS and QLQ-OES24 scores of the two groups increased(P<0.05),and the scores of the observation group were higher than those of the control group(P<0.05).Conclusion Both anlotinib and alpatinib combined with tegafur have certain therapeutic effect in the treatment of advanced esophageal cancer.Compared with alpatinib combined with tegafur,the combination of anlotinib and tegafur is more beneficial to prolong the progression-free survival time and median overall survival,improve short-term efficacy,improve patients’quality of life,and has good safety.

关 键 词：安罗替尼 阿帕替尼 替吉奥 食管癌 

分 类 号：R735.1[医药卫生—肿瘤]